Name

Satio

Legal name

satio, Inc.

Website

https://satiopatch.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Point-of-Care Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)

akta.pro secondary industry

DTx/SaMD Deployment, Integration & Reimbursement Enablement (HLACANAO)

Keywords

• Patch-based diagnostics
• Microneedle drug delivery
• Blood collection devices
• Intradermal delivery
• Medical device patches

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Drug Delivery Patches (SatioRx): Sale of reusable applicators and disposable microneedle patches to pharmaceutical partners and healthcare providers. The reusable device with disposable components creates recurring consumable revenue.
2. Diagnostic Patches (SatioDx): Sale of diagnostic patches incorporating lateral flow assays and biosensor technology to diagnostic and consumer healthcare companies.
3. Blood Collection Patches (SatioDot/SatioDraw): Sale of blood collection patches to CLIA labs and diagnostic companies for laboratory developed tests. Revenue from patch sales to laboratory partners.
4. Licensing and Partnership Revenue: Technology licensing to pharmaceutical companies for drug delivery applications and to diagnostic companies for platform integration. Strategic partnerships with BARDA and ARPA-H provide non-dilutive funding.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Core offering

Satio develops patch-based platforms for at-home blood collection, point-of-care diagnostics, and intradermal drug and vaccine delivery. The portfolio comprises SatioRx (reusable applicator with disposable hollow microneedle arrays for remote-controlled drug delivery), SatioDx (adhesive patch integrating blood draw with lateral flow/biosensor readouts), SatioDot (dried blood spot collection patch for CLIA lab testing), and SatioDraw (whole blood collection patch of approximately 100uL for genomic and clinical tests).

Product overview

Satio develops a portfolio of four distinct patch-based platforms addressing diagnostics and drug delivery. SatioRx™ is a reusable drug delivery patch with microneedle arrays for intradermal/subcutaneous administration. SatioDx™ provides point-of-care blood draw and diagnosis with on-device results. SatioDot™ enables dried blood spot collection for lab-based testing. SatioDraw™ handles whole blood collection for CLIA laboratory testing. Together, these platforms enable decentralized healthcare with at-home diagnostics and drug delivery without needles or professional administration.

Differentiator

Problem solved

Functional benefit

Brands

• SatioDot: Dried Blood Spot (DBS) collection patch for consumer-based sample collection for CLIA labs with laboratory developed tests.
• SatioDraw
• SatioDx
• SatioRx

Products and services

• SatioRx Reusable drug delivery platform with adhesive patch-based microneedle technology enabling stable and controlled intradermal or subcutaneous delivery of liquid medicines. Combines a motor-controlled applicator with disposable hollow non-dissolving microneedle elements, NFC connectivity, and telehealth integration for remote activation and monitoring, supporting 1mL to 5mL drug cartridges and viscosities up to 100cP.
• SatioDx Consumer-based blood draw and diagnostic patch allowing users to collect blood and receive test results directly on the device. Available in Manual and Digital versions, with integrated lateral flow assays and biosensor technology, a lancet port with 130 microliter collection capacity, vacuum-assisted blood draw, and onboard result readout for multi-analyte screening.
• SatioDot Dried blood spot (DBS) collection patch enabling simple, painless, and low-cost consumer-based self-collection for clinical laboratory testing with easy transport and storage, designed for CLIA labs running laboratory developed tests.
• SatioDraw Whole blood collection patch allowing simple consumer-based collection of 100 microliters (range 50–150 microliters) for CLIA labs running laboratory developed tests, supporting diagnosis and whole genome sequencing without fingerstick or mess.

Quantifiable outcome

• Increased payload delivery 2.5-5x compared to typical intradermal delivery
• +5 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• NanowearcoreStrategic or Co-development Partner · 14 April 2025Strategic collaboration to integrate Nanowear's AI-based SimpleSense biomarker platform with Satio's blood draw diagnostics and drug delivery patches. Combines in vivo cardiometabolic biomarkers with in vitro blood diagnostics in a single digital app. Targets $55 billion biopharma clinical research market and $200 billion telehealth segment. First-of-its-kind combination of blood/genotype biomarkers with cardiometabolic physiological data.
• BARDA DRIVecoreStrategic or Co-development Partner · 18 August 2023Contract partnership with Biomedical Advanced Research and Development Authority's Division of Research, Innovation and Ventures (DRIVe) to develop novel patch-based ebolavirus diagnostic. Combines Satio's patch-based blood collection with Institut Pasteur de Dakar's immunoassay. Goal to create low-cost, rapid diagnostic deployable by community health workers in remote settings.
• INTACT SolutionsminorStrategic or Co-development Partner · 23 August 2022Partnership to jointly improve delivery of mass vaccination. Collaborative framework for research, development, manufacture, and deployment of next-generation health technologies using SatioRx intradermal patches for African Union member states.
• Institut Pasteur de DakarcoreStrategic or Co-development Partner · 22 August 2022Strategic partnership for research, development, manufacture, and distribution of next-generation healthcare technologies in Africa. Focuses on enabling low-cost access to vaccines and diagnostics to advance public health. Includes ebolavirus diagnostic immunoassay integration and broader pathogen detection expansion.
• Sapphiros / Sapphiros LaboratoriescoreStrategic or Co-development PartnerManufacturing partnership with Sapphiros for extreme volume manufacturing of diagnostics on their innovative proprietary process. Sapphiros is CLIA certified and operates nationally with comprehensive clinical and digital solutions for collection, testing, and reporting. Ensures low-cost and accessible platform technology for LMICs.
• neoenta designminorStrategic or Co-development PartnerPartner in innovation with hands-on approach to bringing new technologies to life through careful development, cultivation, and incubation.
• NowfutureminorStrategic or Co-development PartnerPartner utilizing state-of-the-art technology to decode and interpret DNA insights most relevant to consumers.
• GoToKnowminorChannel Partner/ Reseller/ DistributorDirect-to-consumer sales channel that empowers customers through a portfolio of diagnostic and genomic tests.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Drawbridge Health: Drawbridge Health's OneDraw device enables single-use, finger-click blood sample collection for lab testing, comparable to SatioDot/SatioDraw for at-home specimen collection feeding CLIA laboratories.
• Tasso: Tasso develops push-button dried blood spot and volumetric absorptive microsampling collection patches for at-home sample collection — a near-identical use case to Satio's SatioDot and SatioDraw platforms, serving CLIA labs and clinical research customers.
• Yourbio (formerly Seventh Sense Biosystems): Yourbio commercializes touch-activated TAP blood-collection microneedle devices for decentralized clinical and at-home diagnostics, directly competing with Satio's whole-blood and DBS patch platforms.
• Micron Biomedical: Micron Biomedical develops dissolvable and seasonal-influenza microneedle patch products for vaccines and drug delivery — directly comparable to SatioRx's intradermal delivery value proposition for biologics and vaccines.
• Vaxxas: Vaxxas is commercializing high-density microarray microneedle patches for vaccine and therapeutic delivery, overlapping directly with SatioRx's microneedle drug-delivery platform and at-home administration thesis.

Broad incumbents

• BD (Becton, Dickinson and Company): BD offers legacy microneedle injection products (e.g., Soluvia/MicroDose) and a broad medical-device portfolio including specimen collection and diagnostic solutions, making it an incumbent competitor across both SatioRx and the blood-collection patch businesses.
• 3M: 3M's Drug Delivery Systems division produces hollow microneedle technologies and transdermal drug-delivery platforms, creating direct overlap with SatioRx across intradermal delivery for vaccines and biologics.
• OraSure Technologies: OraSure is an established player in dried blood spot collection (e.g., OraQuick, Intercept DBS) and at-home sample collection, making it a comparable incumbent serving clinical trials and decentralized testing — the same buyers Satio targets.

Emerging players

• Raphas: Raphas develops dissolving and coated microneedle patches for cosmetics, drugs and vaccines, representing an emerging competitor in the niche microneedle patch space that SatioRx is targeting.

Others

• Sapphiros Laboratories: Sapphiros is Satio's strategic manufacturing and CLIA-lab partner (KKR-backed), providing extreme-volume manufacturing for Satio's diagnostic patches and acting as a distribution channel into CLIA testing services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Satio